We performed the survival analysis by Kaplan–Meier-plot (http://kmplot.com/analysis/) to show that higher expression levels of NAT10 had shorter survival lifetime in lung cancer (P = 0.0072), gastric cancer (P = 4.4E-05), liver cancer (P = 0.037) and sarcoma (P = 0.0053) patients (Fig. 6c). Here, NAT10 is linked to lung carcinoma.